A Malaria Vaccine Technology Roadmap provides a coherent framework for aligning resources, facilitating partnerships, and identifying pathways to a viable malaria vaccine.

Malaria Vaccine Technology Roadmap Launched at Global Vaccine Research Forum

The Malaria Vaccine Technology Roadmap, a new global strategy, was launched December 4, 2006, at the Global Vaccine Research Forum in Bangkok. The Roadmap calls for joint action among the world's leading international health organizations to accelerate the development and licensing of a highly effective malaria vaccine. It seeks to develop a malaria vaccine by 2025 that would have a protective efficacy of more than 80% against clinical disease and would provide protection for longer than four years. The Roadmap establishes a strategic plan for developing and distributing a safe, effective and affordable vaccine to prevent malaria in children under five years of age in sub-Saharan Africa and other highly endemic regions.

"The pace of progress towards a malaria vaccine could dramatically accelerate if these priority areas are successfully pursued," said Dr Melinda Moree, Director of the PATH Malaria Vaccine Initiative which coordinated the development of the Roadmap. "Information sharing and collaboration needs to be stepped up to enhance learning across studies and eliminate redundant work. Above all, continued commitment to this initiative is vital. Developing an effective malaria vaccine is an enormous challenge, but it is within reach."

Press Release: Global Strategy Aims for Effective Malaria Vaccine by 2025 (PDF 70 KB) Download Acrobat Reader

Final Malaria Vaccine Technology Roadmap Released

The final Malaria Vaccine Technology Roadmap has been released, concluding an extensive consultative process that was coordinated by the PATH Malaria Vaccine Initiative along with Energetics Incorporated. The Roadmap is based on the results of a series of five meetings held in 2004 and 2005 (Vision Meeting in Hinxton, UK; Roadmap Meeting in Provence, France; and three Stakeholder Meetings in Bethesda, MD, USA; Durban, South Africa; and Oxford, UK) and a 2006 synthesis process through which key experts carefully reviewed the collective input of the malaria vaccine community.

More than 230 experts representing 100 organizations from 35 countries have participated in the process. The resulting Roadmap presents a shared vision and goal and identifies the community's top priorities for accelerating malaria vaccine development. Members of the WHO-led malaria vaccine funders group, who are each associated with agencies funding malaria vaccine development and contributors to the Roadmap process, have committed to greater coordination and partnership in support of the activities identified in the Roadmap.

We hope that the entire malaria vaccine community also will champion the Roadmap priorities. Together, this dedicated community can implement the priorities identified by our community in this Roadmap in order to reach our shared goal sooner – an effective malaria vaccine that can save lives.

Malaria Vaccine Technology Roadmap (PDF 465 KB)
Executive Summary: Malaria Vaccine Technology Roadmap (PDF 247 KB) Download Acrobat Reader

Malaria Vaccine Technology Roadmap Sessions Held at MIM Conference, ASTMH Annual Meeting

The current status and future plans for the Malaria Vaccine Technology Roadmap were presented during sessions at the Fourth MIM Pan-African Malaria Conference 2005 in Yaoundé, Cameroon, and the American Society of Tropical Medical and Hygiene’s 54th Annual Meeting in Washington, DC.

Speakers at these sessions included:

• Dr. Regina Rabinovich and Dr. Doug Holtzman, Bill and Melinda Gates Foundation
• Dr. Marie-Paule Kieny and Dr. Zarifah Reed, World Health Organization
• Dr. Lee Hall, U.S. National Institutes of Health
• Dr. Melinda Moree, Malaria Vaccine Initiative
• Dr. Fred Binka, INDEPTH Network
• Dr. Graham Brown, WEHI/University of Melbourne
• Dr. Carter Diggs, U.S. Agency for International Development.

Malaria Vaccine Technology Roadmap Briefing – December 2005 (PDF 537 KB) Download Acrobat Reader